Therapeutic vaccines for prostate cancer: recent advances and future directions

Expert Review of Vaccines

Volumn 15, Issue 7, 2016, Pages 907-914

  Strauss, Julius ^a   Madan, Ravi A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Immunotherapy; Prostate Cancer; Vaccines

Indexed keywords

AGLATIMAGENE BESADENOVEC; CANCER VACCINE; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DOCETAXEL; ENZALUTAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T;

ANTIANDROGEN THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CYTOREDUCTIVE SURGERY; HUMAN; IMMUNE RESPONSE; MALE; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VACCINATION; DRUG DEVELOPMENT; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; PROSTATIC NEOPLASMS; SECONDARY PREVENTION; TREATMENT OUTCOME; TRENDS;

CANCER VACCINES; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DRUG DISCOVERY; HUMANS; MALE; PROSTATIC NEOPLASMS; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84961211405     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1155988     Document Type: Review

References (67)

1. S.Hodi, S.J.O’Day, D.F.McDermott, et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEJM. 2010 Aug 19;363(8):711–723.
2. L.Paz-Ares, L.Horn, H.Borghaei, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(suppl; abstr LBA109).
3. C.Robert, G.V.Long, B.Brady, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–330.
4. D.SpigelDr, K.L.Reckamp, N.A.Rizvi, et al. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(suppl; abstr 8009).
5. M.A.Postow, J.Chesney, A.C.Pavlick, et al. Nivolumab and Ipilimumab versus Ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–2017.
6. P.W.Kantoff, C.S.Higano, N.D.Shore, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422.•This phase III trial led to FDA approval of sipuleucel-T for minimally symptomatic mCRPC.
7. E.J.Small, P.F.Schellhammer, C.S.Higano, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24(19):3089–3094.
8. R.Spisek, M.Podrazil, L.Jarolim, et al. Cancer immunotherapy of patients with the biochemical relapse of the prostate cancer using dendritic cell-based vaccine DCVAC/PCa. J Clin Oncol. 2014;32:5s(suppl; abstr 3099).•This phase I/II trial led to an ongoing phase III trial of docetaxel and DCVAC versus docetaxel alone in men with chemotherapy naive mCRPC.
9. D.L.Suzman, X.C.Zhou, M.L.Zahurak, et al. Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials. Prostate Cancer Prostatic Dis. 2015 Mar;18(1):49–55. doi:10.1038/pcan.2014.44. Epub 2014 Nov 11.•This retrospective multivariate analysis of four phase II trials showed that on study changes in PSADT were independently predictive of overall survival.
10. M.Podrazil, R.Horvath, E.Becht, et al. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 2015;6(20):18192–18205.•This phase I/II trial led to an ongoing phase III trial of docetaxel and DCVAC versus docetaxel alone in men with chemotherapy naive mCRPC.
11. R.S.DiPaola, M.Plante, H.Kaufman, et al. A phase I trial of pox PSA vaccines (PROSTVAC) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med. 2006;4:1. article 1
12. M.G.Sanda, D.C.Smith, L.G.Charles, et al. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology. 1999;53(2):260–266.
13. P.M.Arlen, L.Skarupa, M.Pazdur, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urology. 2007 Oct;178(4 Pt 1):1515–1520. Epub 2007 Aug 16.
14. H.L.Kaufman, W.Wang, J.Manola, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern cooperative oncology group. J Clin Oncol. 2004;22(11):2122–2132.
15. P.W.Kantoff, T.J.Schuetz, B.A.Blumenstein, et al. OS analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099–1105.•This phase II trial led to an ongoing phase III trial of prostvac with or without GM-CSF in men with mCRPC.
16. J.L.Gulley, P.M.Arlen, R.A.Madan, et al. Immunologic and prognostic factors associated with OS employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother. 2010;59:663–674.
17. J.R.Herman, H.L.Adler, E.Aguilar-Cordova, et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther. 1999 May 1;10(7):1239–1249.
18. B.J.Miles, M.Shalev, E.Aguilar-Cordova, et al. Prostate-specific antigen response and systemic T-cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 2001 Nov 1;12(16):1955–1967.
19. T.Fujita, B.S.Teh, T.L.Timme, et al. Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):84–90. Epub 2006 Feb 10.
20. L.K.Aguilar, B.The, W.Mai, et al. Five year follow up of a phase II study of cytotoxic immunotherapy combined with radiation in newly diagnosed prostate cancer. J Clin Oncol. 2006;24(18S):4635. 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition), (June 20 Supplement).
21. A.1.Rojas-Martínez, A.G.Manzanera, S.W.Sukin, et al. Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer. Cancer Gene Ther. 2013;20(11):642–649.•Based on this data with Adv-tk, a randomized phase III trial is evaluating standard external beam radiation therapy (EBRT) and valacyclovir with or without Adv-tk and an option for ADT in men with intermediate and high risk localized prostate cancer.
22. P.F.Schellhammer, G.Chodak, J.B.Whitmore, et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from Sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial. Urology. 2013 June;81:1297–1302.•This analysis of the phase III IMPACT trial strongly suggested that sipuleucel-T was more effective in patients with less burden of disease.
23. C.J.Paller, E.S.Antonarakis Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hemato Oncol H&O. 2013;11(1):14–23.
24. R.L.Siegel, K.D.Miller, A.Jemal. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
25. N.Chi, Z.Tan, K.Ma, et al. Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and −6 in prostate cancer. Int J Clin Exp Med. 2014;7(10):3181–3192.
26. L.Fong, P.Carroll, V.Weinberg, et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014;106(11).•This trial was the first to report on immune responses of sipuleucel-T- in the tumor microenvironment.
27. J.L.Gulley, C.R.Heery, R.A.Madan, et al. Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. Cancer Immunology, Immunotherapy: CII. 2013;62(9):1521–1531.
28. B.Farsaci, C.Jochems, I.Grenga, et al. Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets. International journal of cancer. J Int Du Cancer. 2014;135(4):862–870.
29. J.B.Aragon-Ching, K.M.Williams, J.L.Gulley. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci. 2007;12:4957–4971.
30. M.Mercader, B.K.Bodner, M.T.Moser, et al. T-cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Natl Acad Sci USA. 2001;98:14565–14570.
31. T.S.Heng, G.L.Goldberg, D.H.Gray, et al. Effects of castration on thymocyte development in two different models of thymic involution. J Immunol. 2005;175:2982–2993.
32. C.G.Drake, A.D.Doody, M.A.Mihalyo, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell. 2005;7:239–249.
33. E.Antonarakis, A.Kibel, G.Adams, et al. A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): immune results. J Clin Oncol. 2013;31S:Sabstr 5016.
34. A.Ardiani. Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget. 2014 Oct 15;5(19):9335–9348.
35. A.Ardiani, B.Farsaci, C.J.Rogers, et al. Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. Clin Cancer Res. 2013 Nov 15;19(22):6205–6218.
36. E.J.Small, R.Lance, T.A.Gardner, et al. A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol. 2013;31(suppl; abstr 114).
37. E.J.Small, R.S.Lance, C.H.Redfern, et al. A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol. 2013;31(suppl; abstr 5047).
38. R.A.Madan R.N.Donahue H.Singh, et al. Clinical and immunologic impact of short course enzalutamide without androgen deprivation therapy (ADT) for biochemically recurrent prostate cancer. J Clin Oncol. 2016;34(suppl 2S; abstr 214).
39. J.W.Hodge, C.T.Garnett, B.Farsaci, et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer. 2013;133:624–636.
40. Y.Ma, O.Kepp, F.Ghiringhelli, et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol. 2010;22(3):113–124.
41. M.Roselli, V.Cereda, M.Di Bari, et al. Effects of conventional therapeutic interventions on the number and function of regulatory T-cell. OncoImmunology. 2013;2(10):e27025.
42. M.E.Lutsiak, R.T.Semnani, R.De Pascalis, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862–2868.
43. J.Taieb, N.Chaput, N.Schartz, et al. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol. 2006;176:2722–2729.
44. P.M.Arlen, J.L.Gulley, C.Parker, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res. 2006;12(4):1260–1269.
45. C.T.Garnett, C.Palena, M.Chakraborty, et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 2004;64:7985–7994.
46. M.Chakraborty, S.I.Abrams, C.N.Coleman, et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 2004;64:4328–4337.
47. M.Chakraborty, S.I.Abrams, K.Camphausen, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol. 2003;170:6338–6347.
48. C.Garnett-Benson, J.W.Hodge, S.R.Gameiro. Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities. Semin Radiat Oncol. 2015;25(1):46–53.
49. S.M.Hiniker, D.S.Chen, S.J.Knox. Abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(21):2035. author reply 2035-2036.
50. J.L.Gulley, P.M.Arlen, A.Bastian, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res. 2005;11(9):3353–3362.
51. C.R.Heery, R.A.Madan, M.Bilusic, et al. A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-tricom vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel. J Clin Oncol. 2013;31(suppl 6; abstr 102).
52. C.Parker, S.Nilsson, D.Heinrich, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223.
53. G.O’Sullivan Coyne, R.A.Madan, J.L.Gulley. Nivolumab: promising survival signal coupled with limited toxicity raises expectations. J Clin Oncol. 2014 Apr 1;32(10):986–988.
54. K.M.Mahoney, M.B.Atkins. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park). 2014;28(Suppl 3):39–48.
55. A.M.Martin, T.R.Nirschl, C.J.Nirschl, et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Disease. 2015;18:325–332;.
56. S.L.Topalian, F.S.Hodi, J.R.Brahmer, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
57. M.Sznol, L.Chen. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer-response. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2013;19(19):5542.
58. J.Fu, I.J.Malm, D.K.Kadayakkara, et al. Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res. 4042-4052;74(15):2014.
59. A.Ribas. Tumor immunotherapy directed at PD-1. N Engl J Med. 2012;366(26):2517–2519.
60. J.Larkin, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015 July;2015;(373):23–34.
61. R.A.Madan, M.Mohebtash, P.M.Arlen, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet. Oncol. 2012;13(5):501–508.
62. H.Singh, R.A.Madan, W.L.Dahut, et al. Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer. J Clin Oncol. 2015;33(suppl 7; abstr 172).•This trial of prostvac plus ipilumimab in men with mCRPC showed a marked improvement in OS compared to historical controls.
63. E.D.Kwon, C.G.Drake, H.I.Scher, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–712.
64. A.J.Van Den Eertwegh, J.Versluis, H.P.Van Den Berg, et al. Combined immunotherapy with granulocyte- macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):509–517.
65. S.Wada, C.M.Jackson, K.Yoshimura, et al. Sequencing CTLA-4 block- ade with cell-based immunotherapy for prostate cancer. J Transl Med. 2013;11:89.
66. J.H.Finke, B.Rini, J.Ireland, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 2008 October 15;14:6674.
67. J.S.Ko, A.H.Zea, B.I.Rini, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009 Mar 15;15(6):2148–2157.